Search Results
Jun 03, 2026, 10:01 ET T-cell Malignancies Market to Accelerate Substantially at a CAGR of 5.2% During the Forecast Period (2026-2036) | DelveInsight
rates.Rising Opportunities in GGT1-Targeted Therapies: Growing evidence supporting PTX-100's enhanced efficacy and improved safety profile compared with LYMPHIR underscores an expanding opportunity for drug developers to advance therapies focused on GGT1 inhibition.Robust
More news about: DelveInsight Business Research, LLP
May 31, 2026, 08:29 ET RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) pivotal data show strong and durable responses in advanced head and neck cancer where options remain limited
decreased albumin (8%), decreased sodium (7%), increased ALT (7%), decreased potassium (5%), decreased hemoglobin (3.8%), increased AST (3.8%), increased GGT (2.6%), and increased magnesium (2.6%).Serious ARs occurred in 49% of patients, with those occurring in ≥2% of patients including VTE (11%), pneumonia
More news about: Johnson & Johnson
May 29, 2026, 14:00 ET RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer
decreased albumin (8%), decreased sodium (7%), increased ALT (7%), decreased potassium (5%), decreased hemoglobin (3.8%), increased AST (3.8%), increased GGT (2.6%), and increased magnesium (2.6%).Serious ARs occurred in 49% of patients, with those occurring in ≥2% of patients including VTE (11%), pneumonia
More news about: Johnson & Johnson
May 14, 2026, 07:00 ET REGENXBIO Announces Positive Topline Results from Pivotal Phase III AFFINITY DUCHENNE® Study of RGX-202
more than 80% full capsids may contribute to a favorable safety profile for RGX-202. Mean gamma-glutamyl transferase (GGT) and total bilirubin, recognized markers of liver inflammation in Duchenne, did not exceed the upper limit of normal
More news about: REGENXBIO Inc.
May 01, 2026, 09:23 ET DOSE PARTNERS WITH JUICE PRESS TO DEBUT LIMITED-TIME SMOOTHIE, BRINGING CLINICALLY-BACKED WELLNESS TO EVERYDAY RITUALS
placebo-controlled clinical study, more than 80% of participants showed a positive impact on key liver enzyme markers - including ALT, AST, ALP, and GGT - after consistent daily use.*† And 83% of participants reported improvement in occasional bloating after 3 months*† This research
More news about: Dose
Apr 28, 2026, 10:00 ET Untoxicate Launches First-of-Its-Kind Hydration and Liver Support System with At-Home Biomarker Testing and Tracking
are under stress AST (Aspartate Aminotransferase): Commonly evaluated alongside ALT to help assess liver health GGT (Gamma-Glutamyl Transferase): A sensitive marker often associated with alcohol and metabolic stressSamples are collected at home and processed
More news about: Untoxicate
Apr 09, 2026, 08:41 ET Choose Health Launches Comprehensive At-Home GLP-1 Monitoring Panels for Ozempic, Wegovy and Mounjaro Users
GLP-1 Health Monitoring Panel – Basic covers 8 biomarkers including liver enzymes (ALT, AST, GGT), kidney function (creatinine, eGFR), lipase, and blood sugar markers.The
More news about: Choose Health
Apr 02, 2026, 11:00 ET Marin-Sonoma Coordinated Transit Service (MASCOTS) Plan launches April 12, 2026
San Francisco, giving riders more reliable transit options.Along the Highway 101 corridor, many transfers between SMART and GGT Route 101 have been improved to fall within an ideal transfer window of 5–10 minutesThis reduces wait times and overall trip time for ridersRiders
More news about: Metropolitan Transportation Commission
Mar 21, 2026, 13:28 ET TTW Reveals Top 50 Safest Travel Destinations Around the World for 2026
famous swimming pigs.Fly to George Town (GGT).5
More news about: Travel And Tour World
Mar 11, 2026, 11:45 ET REGENXBIO REPORTS NEW POSITIVE INTERIM DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202
pivotal dose participants aged 1 to <12 years at dosing show no evidence of liver injury across multiple measures. Mean gamma-glutamyl transferase (GGT) and total bilirubin, recognized markers of liver inflammation in Duchenne, did not exceed the upper limit of normal up to two years post-treatment.
More news about: REGENXBIO Inc.
Feb 19, 2026, 17:00 ET RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus immunotherapy shows strong clinical benefit with 56 percent overall response rate in first-line recurrent or metastatic head and neck cancer
decreased albumin (8%), decreased sodium (7%), increased ALT (7%), decreased potassium (5%), decreased hemoglobin (3.8%), increased AST (3.8%), increased GGT (2.6%), and increased magnesium (2.6%).Serious ARs occurred in 49% of patients, with those occurring in ≥2% of patients including VTE (11%), pneumonia
More news about: Johnson & Johnson
Feb 18, 2026, 07:30 ET RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Breakthrough Therapy Designation for patients with advanced head and neck cancer
decreased albumin (8%), decreased sodium (7%), increased ALT (7%), decreased potassium (5%), decreased hemoglobin (3.8%), increased AST (3.8%), increased GGT (2.6%), and increased magnesium (2.6%).Serious ARs occurred in 49% of patients, with those occurring in ≥2% of patients including VTE (11%), pneumonia
More news about: Johnson & Johnson
Feb 17, 2026, 08:00 ET FDA approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) as the only EGFR-targeted therapy that can be administered once a month
decreased albumin (8%), decreased sodium (7%), increased ALT (7%), decreased potassium (5%), decreased hemoglobin (3.8%), increased AST (3.8%), increased GGT (2.6%), and increased magnesium (2.6%).Serious ARs occurred in 49% of patients, with those occurring in ≥2% of patients including VTE (11%), pneumonia
More news about: Johnson & Johnson
Jan 10, 2026, 10:00 ET RYBREVANT® (amivantamab-vmjw) longer-term results show promising and durable responses in difficult-to-treat colorectal cancer
decreased albumin (8%), decreased sodium (7%), increased ALT (7%), decreased potassium (5%), decreased hemoglobin (3.8%), increased AST (3.8%), increased GGT (2.6%), and increased magnesium (2.6%).Serious ARs occurred in 49% of patients, with those occurring in ≥2% of patients including VTE (11%), pneumonia
More news about: Johnson & Johnson
Dec 17, 2025, 18:49 ET U.S. FDA Approval of RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Enables the Simplest, Shortest Administration Time for a First-Line Combination Regimen when Combined with LAZCLUZE® (lazertinib)
decreased albumin (8%), decreased sodium (7%), increased ALT (7%), decreased potassium (5%), decreased hemoglobin (3.8%), increased AST (3.8%), increased GGT (2.6%), and increased magnesium (2.6%).Serious ARs occurred in 49% of patients, with those occurring in ≥2% of patients including VTE (11%), pneumonia
More news about: Johnson & Johnson
Dec 11, 2025, 07:47 ET Intensity Therapeutics, Inc. to Present Two Posters at the 2025 San Antonio Breast Cancer Symposium
GGT Increased
More news about: Intensity Therapeutics Inc.
Dec 03, 2025, 07:30 ET ADC Therapeutics Announces Updated Data from LOTIS-7 Phase 1b Clinical Trial of ZYNLONTA® in Combination with Bispecific Antibody Supporting Potential Best-in-Class Regimen in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma
profileGrade 3 or higher treatment emergent adverse events (TEAEs) observed in > 5% of patients included neutropenia (32.7%), GGT increased (16.3%), anemia (10.2%), WBC decreased (8.2%), generalized oedema (8.2%), ALT increased (8.2%), AST increased (6.1%), and thrombocytopenia
More news about: ADC Therapeutics SA
Oct 19, 2025, 10:30 ET Subcutaneous amivantamab delivers promising 45 percent overall response rate with median duration of 7.2 months in recurrent or metastatic head and neck cancer
decreased albumin (8%), decreased sodium (7%), increased ALT (7%), decreased potassium (5%), decreased hemoglobin (3.8%), increased AST (3.8%), increased GGT (2.6%), and increased magnesium (2.6%). Serious ARs occurred in 49% of patients, with those occurring in ≥2% of patients including
More news about: Johnson & Johnson
Sep 22, 2025, 08:05 ET European Commission Approves Servier's VORANIGO® (vorasidenib) as the First Targeted Therapy for Grade 2 IDH-Mutant Glioma in the EU
the results of the Phase 1 trials. Overall, the most common adverse reactions, including laboratory abnormalities, were ALT increased, AST increased, GGT increased, fatigue and diarrhea. About Glioma5Gliomas are tumors that arise from glial or precursor
More news about: Servier Pharmaceuticals
Sep 09, 2025, 12:09 ET Igniton, Inc. Launches A Quantum Leap in Human Wellness
days.IgniLongevity™: Reduced Interleukin-6 (IL-6) by ~50% and C-Reactive Protein (CRP) by ~40%, with significant reductions in blood pressure and GGT liver enzymes within 60 days—supporting measurable decreases in systemic stress and inflammation markers.Igniton's proprietary process
More news about: Igniton Inc.
Sep 07, 2025, 03:22 ET Data published in The New England Journal of Medicine demonstrate RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) is re-setting survival expectations in first-line EGFR-mutated lung cancer
decreased albumin (8%), decreased sodium (7%), increased ALT (7%), decreased potassium (5%), decreased hemoglobin (3.8%), increased AST (3.8%), increased GGT (2.6%), and increased magnesium (2.6%). Serious adverse reactions occurred in 49% of patients who received RYBREVANT® in combination
More news about: Johnson & Johnson
Sep 06, 2025, 03:00 ET RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) prevents acquired resistance versus osimertinib in first-line EGFR-mutated non-small cell lung cancer
decreased albumin (8%), decreased sodium (7%), increased ALT (7%), decreased potassium (5%), decreased hemoglobin (3.8%), increased AST (3.8%), increased GGT (2.6%), and increased magnesium (2.6%). Serious adverse reactions occurred in 49% of patients who received RYBREVANT® in combination
More news about: Johnson & Johnson
Jun 24, 2025, 09:00 ET BioMarin Presents Five-Year Phase 3 Results Reinforcing Long-Term Efficacy and Safety of ROCTAVIAN® (valoctocogene roxaparvovec-rvox) at International Society on Thrombosis and Haemostasis 2025 Congress
reactions, vomiting, and abdominal pain. Most common laboratory abnormalities (incidence ≥ 10%) were ALT, AST, LDH, CPK, factor VIII activity levels, GGT and bilirubin > ULN. Patients also experienced adverse reactions from corticosteroid use. Isotretinoin, Efavirenz, and HIV Positive Patients:
More news about: BioMarin Pharmaceutical Inc.
Jun 12, 2025, 06:30 ET ADC Therapeutics Announces Updated Data from LOTIS-7 Clinical Trial Presented at the European Hematology Association 2025 Congress
higher treatment emergent adverse events (TEAEs) observed in > 5% of patients included neutropenia (24.4%), anemia (9.8%), AST increased (7.3%), GGT increased (7.3%), and thrombocytopenia (7.3%)In the 150 µg/kg dose, cytokine release syndrome (CRS) (23.8%), all of which were Grade 1, and
More news about: ADC Therapeutics SA